GROUPE BRUXELLES LAMBERT NV

Affidea expands in the UK, partnering with LIPS Healthcare to build 40,000‑sq‑ft clinics, boost diagnostic share to 23% and unlock NHS referral flows, driving investor upside.

Groupe Bruxelles Lambert’s Q1 earnings dip fuels a strategic pivot, divesting non‑core assets while acquiring tech‑driven stakes in ophthalmic care and smart‑city traffic management, positioning the firm for long‑term, ESG‑aligned growth amid global…

Groupe Bruxelles Lambert’s share price remains stable, with investors confident in the company’s future prospects and strong fundamentals, positioning it for continued growth and expansion.

Groupe Bruxelles Lambert’s stock price has remained stable, fluctuating within a narrow range of 62.65-72.4 EUR over the past year.